Novo Nordisk Initiates Phase 1 Trial for Novel Obesity Treatment NNC0174-1213

Obesity and overweight are chronic conditions affecting millions globally, significantly increasing the risk of numerous health issues like type 2 diabetes, cardiovascular disease, and certain cancers. Current treatments, while effective, often have limitations in terms of efficacy, side effects, or administration. This Phase 1 study aims to evaluate a new investigational compound, NNC0174-1213, for its safety, tolerability, and preliminary efficacy in individuals with overweight or obesity, addressing the ongoing need for more effective and well-tolerated weight management solutions.

As this study is currently recruiting and set to begin in December 2024, no definitive results are available yet. However, the trial is designed to establish critical foundational data for NNC0174-1213. Researchers will meticulously assess the safety profile, including adverse events and tolerability, across various dose levels in 177 participants. Pharmacokinetic parameters (how the body absorbs, distributes, metabolizes, and excretes the drug) will be thoroughly characterized after both single and multiple administrations. > The primary objective is to determine if NNC0174-1213 is safe and well-tolerated enough to proceed to later-stage clinical development, while also looking for early signals of efficacy in weight reduction compared to placebo and Cagrilintide.